What is the standard DCF (docetaxel, cisplatin, 5‑fluorouracil) induction regimen for locally advanced head and neck squamous cell carcinoma, including dosing, schedule, and eligibility criteria?

DCF Regimen for Locally Advanced Head and Neck Cancer

For locally advanced squamous cell carcinoma of the head and neck (SCCHN), the standard DCF induction regimen consists of docetaxel 75 mg/m² IV over 1 hour on day 1, followed by cisplatin 75-100 mg/m² IV over 1-3 hours on day 1, followed by 5-fluorouracil 750-1000 mg/m²/day as continuous IV infusion for 4-5 days, repeated every 3 weeks for 3-4 cycles, followed by definitive radiotherapy or chemoradiotherapy. 1

Standard Dosing Schedules

The FDA-approved regimens for head and neck cancer include two distinct protocols based on landmark trials:

TAX323 Protocol (Induction → Radiotherapy)

• Docetaxel: 75 mg/m² IV over 1 hour, day 1
• Cisplatin: 75 mg/m² IV over 1 hour, day 1
• 5-FU: 750 mg/m²/day continuous infusion for 5 days
• Cycles: Every 3 weeks × 4 cycles
• Followed by: Radiotherapy alone 1

TAX324 Protocol (Induction → Chemoradiotherapy)

• Docetaxel: 75 mg/m² IV over 1 hour, day 1
• Cisplatin: 100 mg/m² IV over 30 minutes to 3 hours, day 1
• 5-FU: 1000 mg/m²/day continuous infusion for 4 days (days 1-4)
• Cycles: Every 3 weeks × 3 cycles
• Followed by: Chemoradiotherapy with weekly carboplatin 1, 2

Eligibility Criteria

Patients must meet ALL of the following:

• Performance status 0-1 (ECOG)
• Neutrophil count ≥1500 cells/mm³
• Normal hepatic function (bilirubin, AST/ALT, alkaline phosphatase within normal limits)
• Adequate renal function for cisplatin administration
• No history of severe hypersensitivity to docetaxel or polysorbate 80 1

Critical exclusion: Patients with elevated liver enzymes >1.5× ULN have higher rates of febrile neutropenia and should not receive this regimen 1.

Required Supportive Care

Mandatory Premedication

• Dexamethasone: 16 mg/day (8 mg twice daily) for 3 days starting 1 day prior to docetaxel to prevent fluid retention and hypersensitivity reactions 1
• Antiemetics: Required for cisplatin administration
• Hydration: Pre- and post-cisplatin hydration protocols 1

Prophylactic Antibiotics

All patients must receive prophylactic antibiotics (e.g., ciprofloxacin) during the neutropenic period, typically days 5-15 of each cycle. This was mandatory in both TAX323 and TAX324 trials 1, 3. The high rate of febrile neutropenia (19-35% in clinical trials) makes this non-negotiable 4, 5.

Clinical Evidence and Efficacy

The TAX324 trial demonstrated superior long-term outcomes with TPF induction followed by chemoradiotherapy versus cisplatin/5-FU alone, with 5-year overall survival of 52% vs 42% (HR 0.74, p=0.014) and median survival of 70.6 vs 34.8 months 2. This represents the highest quality evidence supporting the DCF regimen.

Response rates with DCF induction:

• Overall response: 78-93% 3, 4
• Complete response: 40-54% 4
• Pathologic complete response at primary site: 72% 4

Dose Modifications

Hold treatment if:

• Neutrophils <1500 cells/mm³
• Grade 3-4 febrile neutropenia occurs
• Grade 3-4 renal toxicity develops 1

Dose reduction strategy:

• If febrile neutropenia occurs despite prophylactic antibiotics, add G-CSF to subsequent cycles
• If toxicity persists, reduce docetaxel to 60 mg/m² 1
• Consider split-dose cisplatin (30-40 mg/m² on days 1 and 8) if tolerability is a concern, though this is not FDA-approved 6

Critical Pitfalls to Avoid

1. Do not use 100 mg/m² docetaxel in previously treated patients—this dose is associated with increased treatment-related mortality 1

2. Do not skip prophylactic antibiotics—febrile neutropenia rates are 19-35% even with prophylaxis 4, 5

3. Do not omit dexamethasone premedication—severe fluid retention and hypersensitivity reactions can be life-threatening 1

4. Monitor for cisplatin toxicity: Grade 3-4 hypomagnesemia/hypocalcemia occurs in 30% of patients; hearing loss in 5% 4

5. Timing matters: Median time from last chemotherapy cycle to starting radiotherapy should be approximately 3 weeks 5

Controversy: Induction vs. Concurrent Chemoradiation

The NCCN guidelines reflect a category 3 recommendation (major disagreement among panel members) regarding whether induction chemotherapy followed by chemoradiation should be used versus proceeding directly to concurrent chemoradiation for PS 0-1 patients 7. However, for patients at high risk of distant metastases or requiring organ preservation, induction TPF followed by chemoradiotherapy is the evidence-based approach based on TAX324 trial results showing superior overall survival 2.

For standard locally advanced disease without these specific indications, concurrent high-dose cisplatin (100 mg/m² every 3 weeks) with radiotherapy remains the category 1 preferred option 7.